Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04003623
Recruitment Status : Terminated (The study was closed due to lack of enrollment.)
First Posted : July 1, 2019
Results First Posted : April 21, 2022
Last Update Posted : May 10, 2022
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumors harboring activating FGFR mutations or translocations.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Solid Tumors FGFR Mutations FGFR Translocations Drug: Pemigatinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Participants will be assigned to 1 of 2 cohorts (Cohort A: FGFR1-3 in-frame fusions or FGFR2 intron 17 rearrangements; Cohort B: Known/predicted activating point mutations in FGFR1-3 [excluding kinase domain]) but there is no difference in the treatment regimen between the cohorts.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)
Actual Study Start Date : October 31, 2019
Actual Primary Completion Date : June 12, 2020
Actual Study Completion Date : June 12, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Pemigatinib

Arm Intervention/treatment
Experimental: Pemigatinib Drug: Pemigatinib
Pemigatinib administered orally once daily.
Other Name: INCB054828

Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to approximately 6 months ]
    Defined as the proportion of participants in each cohort who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Secondary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Up to approximately 6 months ]
    Defined as the time from first dose until progressive disease (per RECIST v1.1 or Response Assessment in Neuro-Oncology [RANO]) or death (whichever is first) in each cohort.

  2. Duration of Response (DOR) [ Time Frame: Up to approximately 6 months ]
    Defined as the time from the date of first assessment of CR or PR until the date of the first progressive disease (per RECIST v1.1 or RANO) or death (whichever is first) in each cohort.

  3. Disease Control Rate (DCR) [ Time Frame: Up to approximately 6 months ]
    Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease per RECIST v1.1 or RANO.

  4. Overall Survival (OS) [ Time Frame: Up to approximately 6 months ]
    Defined as the time from first dose of study drug to death of any cause in each cohort.

  5. Number of Treatment-related Adverse Events [ Time Frame: Up to approximately 6 months ]
    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic (Stage IIIB or IV) or is surgically unresectable.
  • Radiographically measurable disease (per RECIST v1.1 or RANO for primary brain tumors).
  • Documentation of an FGFR1-3 gene mutation or translocation.
  • Objective disease progression after at least 1 prior therapy.
  • Not eligible or able to participate in any other Incyte-sponsored clinical trial.

Exclusion Criteria:

  • Advanced/metastatic bladder cancer or advanced/metastatic cholangiocarcinoma.
  • Prior receipt of a selective FGFR inhibitor.
  • Current evidence of clinically significant corneal or retinal disorder.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04003623

Layout table for location information
United States, California
Compassionate Cancer Care Medical Group
Fountain Valley, California, United States, 92708
United States, Florida
Ocala Oncology Center
Ocala, Florida, United States, 34474
United States, Hawaii
Hawaii Cancer Care
Honolulu, Hawaii, United States, 96813
United States, Illinois
Illinois Cancer Care
Peoria, Illinois, United States, 61615
United States, Maryland
FMH James M Stockman Cancer Institute
Frederick, Maryland, United States, 21702
United States, New Jersey
New Jersey Cancer Care and Blood Disorders
Belleville, New Jersey, United States, 07109
United States, Ohio
Cincinnati, Ohio, United States, 45220
United States, South Dakota
Sanford Cancer Center
Sioux Falls, South Dakota, United States, 51704
United States, Texas
Mary Crowley Cancer Center
Dallas, Texas, United States, 75230
Oncology Consultants
Houston, Texas, United States, 77030
United States, Utah
Utah Cancer Specialists
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Study Director: Incyte Medical Monitor Incyte Corporation
  Study Documents (Full-Text)

Documents provided by Incyte Corporation:
Study Protocol  [PDF] June 14, 2019
Statistical Analysis Plan  [PDF] June 21, 2021

Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT04003623    
Other Study ID Numbers: INCB 54828-MA-TA-208
First Posted: July 1, 2019    Key Record Dates
Results First Posted: April 21, 2022
Last Update Posted: May 10, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access Criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Advanced solid tumor
metastatic solid tumor
FGFR inhibitor
FGFR mutation
FGFR translocation
Additional relevant MeSH terms:
Layout table for MeSH terms